Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR... see more

Bullboard (TSX:OPS)

View:
Comment by ddogoldon Dec 24, 2022 8:28am

RE:RE:RE:RE:RE:Raymond James

Patience is still necessary here . I also was disappointed at the $1.90 financing . Best wishes for the holiday season and here's to a successful 2023 .
Comment by bossuon Dec 23, 2022 2:10pm

RE:Necessary to have funds to develop...

FromSarugaser “We continue to have strong long-term conviction that SavvyWire’s unique 3-in-1 TAVR capability represents compelling commercial potential that could drive OPS’ top-line revenue to $100 ...more  
Comment by Possibleidiot01on Dec 23, 2022 11:52am

RE:RE:RE:RE:Raymond James

Also a shelf prospectus filed, in case more money is needed. which gives potential access to more capital.
Comment by Qccity1on Dec 23, 2022 10:51am

RE:OPSSF

And volume in the US has increased lately. Some people in the States must see the huge potential of the Savvywire. Especially the interventionist cardios who have tried it.
Post by ivebeenthereon Dec 23, 2022 10:13am

OPSSF

Meanwhile in the US Opsens is up 0.03 cents or 2 1/4 %
Comment by ivebeenthereon Dec 23, 2022 10:07am

RE:RE:RE:Raymond James

Maybee they are playing the disappointed suitors, its the second financing in two years by Stiefel GMP. To me it's a great show of confidence. Let Raymond James lick his wounds. GLTA
Comment by Pt6238on Dec 23, 2022 10:04am

RE:RE:RE:Raymond James

Poor time management for this financing! It is entirely Management's fault  
Comment by Qccity1on Dec 23, 2022 9:51am

RE:RE:Raymond James

Mr. Sarugaser seems frustrated about the financing at 1.90$... 
Comment by retiredcfon Dec 23, 2022 9:46am

RE:Raymond James

Hard to believe that someone would punch out their shares for $1.80 at the open based on this. GLTA
Post by retiredcfon Dec 23, 2022 7:30am

Raymond James

Following Thursday’s close of an $11.5-million bought deal equity financing, Raymond James analyst Rahul Sarugaser expects investor sentiment toward Opsens Inc.  will remain “cool” in ...more  
Post by retiredcfon Dec 23, 2022 6:51am

Top Gainers

Just cracked the list. Good to get back to the financing level on another tough day in the markets. GLTA Symbol/ Company Price $ Change $ Volume  ...more  
Post by bossuon Dec 22, 2022 8:51pm

Necessary to have funds to develop...

OPS is taking ''preventive''step to expand and demonstrate their outstanding product going forward ! Actually 300 persons  or so are working on the production and development to ...more  
Post by ivebeenthereon Dec 22, 2022 1:24pm

Back to normality

TSX down 1.9% Opsens up 3.35% glta
Comment by ivebeenthereon Dec 22, 2022 9:38am

RE:Good to See

We should reach 1.90 in no time then return to the ascending corridor. GLTA And Merry Christmas!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities